Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - December 2026, European Medicines Agency, Amsterdam, the Netherlands, from 16 December 2026, 10:00 (CET) to 16 December 2026, 12:00 (CET)

Human medicines European public assessment report (EPAR): Tyverb, lapatinib, Date of authorisation: 10/06/2008, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Imlygic, talimogene laherparepvec, Date of authorisation: 16/12/2015, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date of authorisation: 14/01/2015, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Spedra, avanafil, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 16, Status: Authorised

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 11 November 2025, 09:30 (CET) to 11 November 2025, 13:00 (CET)

Human medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorised

Healthcare Professionals' Working Party

Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Vaxneuvance, pneumococcal polysaccharide conjugate vaccine (adsorbed), Date of authorisation: 13/12/2021, Revision: 8, Status: Authorised